Twelve optically pure enantiomers were obtained using either crystallization or chiral high performance liquid chromatography (HPLC) separation methodologies to resolve six racemic sigma-1 (r 1 ) receptor ligands. The in vitro binding affinities of each enantiomer for r 1 , r 2 receptors and vesicular acetylcholine transporter (VAChT) were determined. Out of the 12 optically pure enantiomers, five displayed very high affinities for r 1 (K i < 2 nM) and high selectivity for r 1 versus r 2 and VAChT (>100-fold). The minus enantiomer, (À)-14a ((À)-TZ3108) (K i-r1 = 1.8 ± 0.4 nM, K i-r2 = 6960 ± 810 nM, K i-VAChT = 980 ± 87 nM), was chosen for radiolabeling and further in vivo evaluation in rodents and nonhuman primates (NHPs). A biodistribution study in Sprague Dawley rats showed brain uptake (%ID/gram) of (À)-[ 
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Introduction
Sigma (r) receptors are recognized as a non-opioid receptor family and have their own specific bioactivity binding patterns; they have a characteristic anatomical expression, unique properties, and modulation functions in the central nervous system (CNS).
1,2 They are also present in the endocrine and immune systems, and extensively distribute in both the brain and peripheral tissues, where they play an important role in cellular and organ processes including immunoregulation, motor and endocrine function, modulation of proliferation, and regulation of ion channels.
2,3
Two distinct r receptor subtypes, termed r 1 and r 2 , have been characterized based on pharmacological data. [4] [5] [6] The r 1 receptor is a 29 kDa single polypeptide located on the outer membranes of cells; it is a small transmembrane protein cloned in 1996 which consists of 223 amino acids. It has no homology with any other reported mammalian receptor protein.
ligands are recognized as potent neuromodulators for various excitatory neurotransmitter systems including cholinergic, dopaminergic, and glutamatergic systems.
11
PET is a well-established imaging modality that is able to provide functional information by quantitatively assessing the changes of neurotransmitter receptors, transporters and enzymes in brain regions of living subjects.
12,13 PET with suitable r 1 receptor radiotracer will provide a noninvasive methodology for quantifying the expression levels of r 1 receptor in vivo. PET is a useful tool in diagnosis of diseases at early stage and in guiding the development of therapeutics targeting r 1 receptor. 1 Tremendous efforts have been put into identification of a clinically suitable r 1 PET radiotracer.
14 Among the lead r 1 radiotracers, 1-(4-methoxy- Fig. 1 In our search for a clinically suitable r 1 PET tracer, we previously reported a series of carbonyl containing racemic prezamicol analogues (14a-14f, Fig. 1 ) 27 with high r 1 binding affinity and high selectivity for r 1 over r 2 and VAChT (K i-r1 ranging from 0.48 to 26 nM, >100-fold selectivity for r 1 over both r 2 and VAChT). These racemic compounds were made by replacing the 4-phenylpiperidinyl group in prezamicol with a 4-substituted benzoylpiperidinyl group and alkylating the secondary amine in (3 0 -hydroxy-1,4 0 -bipiperidin-4-yl)(4-substituted phenyl)methanone. These newly developed compounds are structurally similar to the prezamicol scaffold. We also reported our preliminary evaluation of a representative racemic compound, [ were synthesized according to our reported procedures, with the regioselective ring-opening of the epoxy as a key step. 27, 28 The chiral resolutions of the racemic compounds 14a-f and TZ3138 were accomplished using two different methodologies: a) selective 
